Topic:

Regulatory

Latest Headlines

Latest Headlines

Novartis eyes psoriasis dominance with new approvals for Cosentyx

Novartis scored FDA and European approvals this week for its blockbuster contender Cosentyx. But rival companies are developing their own therapies, and existing drugs challenge its market share.

Hospira gets FDA nod for wireless infusion pump, finishing up two-year plan to reinvigorate devices

Hospira hopes to get back on track with its infusion pump business this year. The latest bit of good news for the company is FDA clearance for the Plum 360 Infusion System, which adds the capability to wirelessly stream data to an electronic medical record and access an expanded drug library for information to maintain patient safety.

U.K. expands Wockhardt ban

In 2013, U.K. and European regulators banned most products from a Wockhardt plant in India that was found faking data, but the U.K. allowed it to continue shipping a few that were required for essential medicines. This week, the U.K. stiffened the action to include all active ingredients from Wockhardt's plant in Chikalthana, a facility the FDA has also banned from shipping to the U.S.

Celator's delivery platform results in FDA's fast-track designation for its cancer candidate

Celator Pharmaceuticals received fast-track designation for its candidate for the treatment of secondary acute myeloid leukemia in elderly patients. CPX-351 is designed to achieve sustained release of the anticancer drugs cytarabine and daunorubicin in a precise ratio.

J&J eyes long-acting boost for Invega franchise with quick FDA look at new formula

Johnson & Johnson's antipsychotic med Invega Sustenna is already bringing in blockbuster-plus sales for J&J, and if the company has its way, a new, even longer acting formula will give the franchise an even bigger boost.

UPDATED: Novartis scores the first victory in a blockbuster psoriasis race

Novartis picked up FDA and European approvals to sell its secukinumab as a treatment for psoriasis, the first steps in the company's plot to build a global anti-inflammatory contender and outpace its rivals.

Apple CEO's visit to Congress a sign of growing engagement with the feds

Apple has growing med tech ambitions, but those gnarly healthcare regulations have left a sour taste in its mouth. As a result, the Silicon Valley bigwig has stepped up its engagement with the feds, seeking not only to learn by meeting with the FDA but also to change the rules via a lobbying effort that cost nearly $3 million last year.

Gilead, AbbVie rack up new payer deals, but hep C obstacles loom across the Atlantic

The hepatitis C market is breaking new ground all over the place. As payers put the squeeze on Gilead Sciences and AbbVie for discounts in the U.S., England's National Health Service is delaying a broad rollout of Gilead's blockbuster Sovaldi till July, citing the drug's high cost--an unprecedented move on a treatment already blessed by the country's cost-effectiveness watchdogs.

FDA to avoid regulating most wearables, seeking to reduce device accessory regulation overall

The FDA said in a draft guidance issued last week that it does not intend to regulate general wellness products, which include an array of consumer-oriented wearables like Fitbit's exercise trackers.

CytRx surges after FDA lifts a partial hold on late-stage cancer drug

Shares of CytRx bounced up 10% this morning as investors responded to the news that the FDA had lifted its partial hold on its late-stage cancer drug aldoxorubicin.